Pre-exposure prophylaxis (PrEP) – free webinar

Gus Cairns
Published: 18 April 2013

As part of its European HIV prevention work, NAM is collaborating with AVAC to provide a series of webinars (conference calls with accompanying slides) to train and inform prevention advocates and anyone interested in the newest developments in HIV prevention technology.

The fourth webinar is entitled:

PrEP – news from studies in Europe and elsewhere

This 90-minute webinar will look at the current situation regarding pre-exposure prophylaxis (PrEP) in Europe and the US. It will look at the ongoing IPERGAY study in France and the PROUD study in England, as well as reviewing progress in the NEXT-PrEP and demonstration studies in the US. It will also discuss the implications of the negative results of the recent VOICE trial. The presentations will be followed by a question and answer session with our expert speakers. The webinar will be conducted in English.

Time and date: 2pm UK time (BST), Thursday 9 May (3pm CEST)

The speakers for this month's webinar include:

  • Sheena McCormack, UK Medical Research Council: PROUD trial update.
  • Bruno Spire, Agence nationale de recherches sur le sida et les hépatites virales (ANRS): IPERGAY trial update.
  • Mitzy Gafos, UK Medical Research Council: social science research and PrEP.
  • Matthew Williams, UKCAB: community involvement in PROUD and PrEP trials in general.

To register for the webinar and get phone numbers and joining instructions click this link:

European advocates interested in learning more about PrEP, the opportunities and challenges it may present for existing ways of doing HIV prevention work, and possible barriers to its implementation, are encouraged to join this webinar and to email questions in advance to During the event, participants will be encouraged to ask questions by telephone.

This project has been supported via a grant from Gilead Sciences Europe Ltd.

Gilead Sciences Europe Ltd has provided funding for this project and has had no editorial control over the content of the materials.

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.